Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Invested Capital (2016 - 2025)

Guided Therapeutics' Invested Capital history spans 16 years, with the latest figure at -$5.0 million for Q3 2025.

  • For Q3 2025, Invested Capital fell 17.17% year-over-year to -$5.0 million; the TTM value through Sep 2025 reached -$5.0 million, down 17.17%, while the annual FY2024 figure was -$4.3 million, 31.45% down from the prior year.
  • Invested Capital for Q3 2025 was -$5.0 million at Guided Therapeutics, down from -$4.9 million in the prior quarter.
  • Across five years, Invested Capital topped out at -$2.1 million in Q3 2022 and bottomed at -$7.9 million in Q1 2021.
  • The 5-year median for Invested Capital is -$4.3 million (2024), against an average of -$4.5 million.
  • The largest annual shift saw Invested Capital skyrocketed 70.38% in 2022 before it tumbled 50.27% in 2023.
  • A 5-year view of Invested Capital shows it stood at -$5.4 million in 2021, then soared by 57.66% to -$2.3 million in 2022, then tumbled by 41.81% to -$3.3 million in 2023, then tumbled by 31.45% to -$4.3 million in 2024, then fell by 17.85% to -$5.0 million in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Invested Capital are -$5.0 million (Q3 2025), -$4.9 million (Q2 2025), and -$4.5 million (Q1 2025).